Invitation to SenzaGen’s 2021 half year report conference call on Aug 19 at 10.30 CET

SenzaGen is pleased to invite press and investors to a conference call on Thursday August 19 at 10.30 CEST where CEO Axel Sjöblad comments SenzaGen’s 2021 half year results. The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for the conference
To participate in the conference call, use the dial-in numbers below.

SE: +46850558358
FR: +33170750721
DE: +4969222239166
CH: +41225805976
NE: +31107129163
UK: +443333009260

Weblink
https://tv.streamfabriken.com/senzagen-q2-2021

Contacts

Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com| Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com| Mobile: +46 708-20 29 44

About us

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen’s GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. 

Attachments

Invitation to SenzaGen’s 2021 half year report conference call on Aug 19 at 10.30 CET